Pfizer (PFE)
25.19
+0.15 (0.60%)
NYSE · Last Trade: Dec 19th, 9:36 PM EST
Detailed Quote
| Previous Close | 25.04 |
|---|---|
| Open | 25.01 |
| Bid | 25.20 |
| Ask | 25.25 |
| Day's Range | 24.98 - 25.52 |
| 52 Week Range | 20.92 - 27.69 |
| Volume | 87,590,000 |
| Market Cap | 141.23B |
| PE Ratio (TTM) | 14.65 |
| EPS (TTM) | 1.7 |
| Dividend & Yield | 1.720 (6.83%) |
| 1 Month Average Volume | 53,110,935 |
Chart
About Pfizer (PFE)
Pfizer is a global biopharmaceutical company that develops and manufactures innovative medicines and vaccines to improve health outcomes for people around the world. Renowned for its extensive research and development efforts, Pfizer focuses on various therapeutic areas including vaccines, oncology, immunology, cardiology, endocrinology, and rare diseases. The company is committed to addressing significant health challenges through the discovery of new treatments, leveraging cutting-edge science and technology. Pfizer also emphasizes partnerships and collaborations to expand its capabilities and enhance access to healthcare solutions. Read More
News & Press Releases
On this day in late 2025, Eli Lilly and Company (NYSE: LLY) stands as the undisputed titan of the global pharmaceutical industry. Having crossed the historic $1 trillion market capitalization threshold earlier this year, Lilly has transcended the traditional boundaries of a "Big Pharma" company to become a high-growth technology-like play on human longevity and [...]
Via PredictStreet · December 18, 2025
As of December 16, 2025, Windlas Biotech Limited (NSE: WINDLAS, BSE: 543403) stands as a significant player in India's burgeoning pharmaceutical sector, primarily recognized for its robust contract development and manufacturing organization (CDMO) services. Established in 2001, the company has carved a niche as one of the top five domestic pharmaceutical formulations CDMO providers by [...]
Via PredictStreet · December 16, 2025
This year has been one to forget for these pharmaceutical giants.
Via The Motley Fool · December 19, 2025
The deals expand the pricing program to most targeted drugmakers in exchange for temporary tariff relief.
Via Stocktwits · December 19, 2025
Dow Jones stock Merck forged a Most Favored Nation agreement with the Trump administration on Friday.
Via Investor's Business Daily · December 19, 2025
Curious about the most active S&P500 stocks in today's session? Join us as we explore the US markets on Friday and uncover the stocks that are leading the way in terms of trading volume and market attention.
Via Chartmill · December 19, 2025
Your decision on whether to invest now depends to some extent on your investment strategy.
Via The Motley Fool · December 19, 2025
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner.
Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.
Via StockStory · December 18, 2025
The stocks listed here trade at forward earnings multiples of less than 18.
Via The Motley Fool · December 18, 2025
These two stocks have been going in opposite directions over the past few years.
Via The Motley Fool · December 18, 2025
The United States economy is finally emerging from a period of unprecedented statistical darkness. Following the conclusion of the longest government shutdown in American history—a 43-day impasse that paralyzed Washington from October 1 to November 12, 2025—the release of the November Consumer Price Index (CPI) data today, December
Via MarketMinute · December 18, 2025
Via Benzinga · December 18, 2025
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EST on Tuesday, February 3, 2026. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Fourth Quarter and Full Year 2025 Performance Report, to be issued that morning.
By Pfizer Inc. · Via Business Wire · December 18, 2025
Via Benzinga · December 18, 2025
The financial markets, often perceived as bastions of rational decision-making, are, in reality, deeply swayed by the powerful currents of human emotion. As the global economy navigates its inherent cycles, the interplay of fear and greed emerges as a dominant force, particularly during periods of market downturns. This psychological phenomenon
Via MarketMinute · December 17, 2025
The healthcare industry has never been a great source of dividends -- that alone makes these companies exceptional.
Via The Motley Fool · December 17, 2025
The potential agreements would mark another step in Washington’s broader effort to reshape drug pricing.
Via Stocktwits · December 17, 2025
Curious about the most active S&P500 stocks in today's session? Get insights into the stocks that are leading the way in terms of trading volume and market attention.
Via Chartmill · December 17, 2025
Shares of biotechnology company Moderna (NASDAQ:MRNA)
jumped 4% in the afternoon session after the broader biotech sector experienced a strong rebound, lifting shares of companies within the industry.
Via StockStory · December 17, 2025
Pfizer's shares look attractive to investors willing to show patience.
Via The Motley Fool · December 17, 2025
FDA approves a new Depo-Provera warning on meningioma risk as Pfizer faces lawsuits alleging delayed disclosure of brain tumor concerns.
Via Benzinga · December 17, 2025
The Nasdaq Composite (IXIC) has been on a rollercoaster ride as 2025 draws to a close, experiencing a notable three-day losing streak before showing a modest rebound on December 17. This recent volatility has ignited discussions around an "AI bubble" and raised questions about the sustainability of the tech sector's
Via MarketMinute · December 17, 2025
New York, NY – December 17, 2025 – The Dow Jones Industrial Average (DJIA) has concluded December 2025 with a notable ascent, marking a period of robust performance that has seen the index reach new all-time record highs. This upward momentum, however, unfolds against a complex and often contradictory economic landscape, characterized
Via MarketMinute · December 17, 2025
Pfizer & Merck are the boring intentional reset w/flat growth expectations. Pfizer now offers high dividends, Merck offers reliability.
Via Benzinga · December 17, 2025
It doesn't have the highest yield, but it has enviable dividend coverage and a long history of surviving in a competitive industry.
Via The Motley Fool · December 17, 2025